COMMUNIQUÉS West-GlobeNewswire
-
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
29/07/2026 -
Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease
29/07/2026 -
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
29/07/2026 -
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
29/07/2026 -
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
29/07/2026 -
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
29/07/2026 -
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
29/07/2026 -
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
29/07/2026 -
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
29/07/2026 -
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
29/07/2026 -
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
29/07/2026 -
Alira Health Establishes Annabel de Maria Memorial Scholarship to Inspire the Next Generation of Healthcare Leaders
29/07/2026 -
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
29/07/2026 -
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
28/07/2026 -
Healthcare Executives Signal Growing Strategic Value of Laboratory Services, Siemens Healthineers Survey Finds
28/07/2026 -
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
28/07/2026 -
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
28/07/2026 -
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
28/07/2026 -
Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness
28/07/2026
Pages